Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05220202
Other study ID # IIR 20-256
Secondary ID IRB # 1672072
Status Recruiting
Phase N/A
First received
Last updated
Start date September 20, 2023
Est. completion date December 1, 2026

Study information

Verified date September 2023
Source VA Office of Research and Development
Contact Florine Pore-Brown, BS
Phone (214) 857-3291
Email florine.pore-brown@va.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed study seeks to evaluate effectiveness, implementation processes, and cost of MOTIVATE among older Veterans with chronic musculoskeletal (MSK) pain and comorbid depressive symptoms.


Description:

Investigators will conduct a randomized controlled trial (RCT) at two large VA facilities, to establish the effectiveness and scalability of MOTIVATE, a remotely delivered behavioral intervention for older Veterans with comorbid musculoskeletal (MSK) pain and depressive symptoms. The central hypothesis is that MOTIVATE will improve important patient-centered outcomes among older Veterans with co-occurring MSK pain and depressive symptoms.


Recruitment information / eligibility

Status Recruiting
Enrollment 264
Est. completion date December 1, 2026
Est. primary completion date October 1, 2026
Accepts healthy volunteers No
Gender All
Age group 60 Years to 99 Years
Eligibility Inclusion Criteria: - Aged 60 and older - English- speaking - Self-reported MSK pain (include cLBP +/- radiating symptoms, OA, fibromyalgia) on most days for the past 3 months that interferes with daily activities - Pain intensity that is 4+/10 on the numerical pain rating scale - Pain interference threshold 5+ on PEG-3 - Depressive symptoms, 10+ on PHQ-9 - Capable of participating in home-based activity - Interested in participating in a non-pharmacologic program Exclusion Criteria: - Aged 59 or less - No telephone - Not English speaking - Unwilling to be randomized to either study arm - Not interested in participating in a non-pharmacologic program - Self-reported uncorrected hearing and visual impairments precluding ability to participate in telephone sessions or read pedometer screen - Significant (moderate or severe) cognitive impairment (3+ errors) on six-item screening exam - Self-reported dependence on wheelchair, bed-bound, or severe balance impairment or severe OA* (resulting in inability to participate in physical activity intervention) - Illness requiring hospitalization within the last 3 months that interferes with a home-based physical activity intervention (e.g., fall, gout attack, stroke, heart attack, heart failure, surgery for blocked arteries) - Suicidal intent (see suicide screening protocol), uncontrolled psychotic disorder or psychiatric hospitalization within 1 year, or enrolled in active substance use program (confirmed with scripted protocol over telephone)

Study Design


Intervention

Behavioral:
Behavioral Intervention Group (MOTIVATE)
Behavioral: Behavioral Intervention Group (MOTIVATE) The behavioral intervention is designed for older Veterans with musculoskeletal pain and depression and will include 8 individual telephone sessions delivered by health coaches (for up to 5 months total), accounting for additional time between sessions (if needed).

Locations

Country Name City State
United States VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX Dallas Texas
United States Michael E. DeBakey VA Medical Center, Houston, TX Houston Texas

Sponsors (3)

Lead Sponsor Collaborator
VA Office of Research and Development Dallas VA Medical Center, Michael E. DeBakey VA Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Outcome: Pain interference Pain interference will be assessed using the interference subscale of the Brief Pain Inventory (BPI) score at 3 months post-baseline or completion of MOTIVATE. Patient-reported pain-related interference (0-10 scale, with higher values indicating more pain) has been shown to be sensitive to change and to have good reliability. A mean between-group difference of 1-point in the primary outcome (change of BPI interference score from baseline to 3 months) is considered a clinically meaningful difference. 3 months post baseline or completion of MOTIVATE
Secondary Depressive symptoms, PHQ-9 Depressive symptom severity will be assessed using the PHQ-9, a validated 9 question instrument used for monitoring and measuring the severity of depression symptoms. A cutoff score of >10 signifies clinically meaningful symptom burden Baseline, Mid (~5 weeks), End (~3 months) and 6 months
Secondary Arthritis self-efficacy Arthritis self-efficacy scale is a 10 point Likert scale that measures the belief or confidence the subject has to perform 8 specific activities or tasks, based on arthritis Scale range 1-10: 1) very uncertain to 10) very certain Baseline, Mid (~5 weeks), End (~3 months) and 6 months
Secondary Pain Catastrophizing Pain catastrophizing, a prominent pain behavior construct, can influence response to treatment for chronic musculoskeletal pain. Scale range 0-4: 0 (not at all) to 4 (all the time) Baseline, Mid (~5 weeks), End (~3 months) and 6 months
Secondary Psychological resilience Psychological resilience will be measured by Connor-Davidson Resilience Scale (CD-RISC). scale range 0-4: 0 (not at all) to 4 (all the time) Baseline, Mid (~5 weeks), End (~3 months) and 6 months
Secondary Pain Behavior NIH PROMIS short forms, for pain behavior have shown to have excellent psychometric properties in chronic pain. Scale range 1-6: 1 (No pain) to 6 (Always) Baseline, Mid (~5 weeks), End (~3 months) and 6 months
Secondary Quality of Life using PROMIS Global Health Scale NIH PROMIS short forms, for quality of life (PROMIS Global Health scale (physical and mental health) have shown to have excellent psychometric properties in chronic pain. Scale range 5-1: 5 (Excellent) to 1 (Poor) Baseline, Mid (~5 weeks), End (~3 months) and 6 months
Secondary Social Functioning NIH PROMIS short forms, for social functioning have shown to have excellent psychometric properties in chronic pain. Scale range 1-5: 1 (Never) to 5 (Always) Baseline, Mid (~5 weeks), End (~3 months) and 6 months
Secondary Sleep Disturbance 8-item PROMIS Sleep disturbance short form is well validated using objective sleep assessment tools (e.g., actigraphy) and used routinely in chronic pain patients and older adults. Scale range 5-1: 5 (very poor) to 1 (very good) Baseline, Mid (~5 weeks), End (~3 months) and 6 months
Secondary Insomnia Severity Index The 7-item Insomnia severity index (ISI) will assess severity of both nighttime and daytime components of insomnia scale ranges: 0 - 7 No clinically significant insomnia; 8 - 14 Subthreshold insomnia; 15 - 21 Clinical insomnia (moderate severity); 22 - 28 Clinical insomnia (severe) Baseline, Mid (~5 weeks), End (~3 months) and 6 months
Secondary Patient Global Impression of change scale Patient Global Impression of Change Scale, recommended as a core outcome measure in pain trials, will be assessed. scoring range is 1-7: 1) "no change" to 7) "a great deal better" Baseline, Mid (~5 weeks), End (~3 months) and 6 months
Secondary FRAIL scale FRAIL measures frailty among older adults. scoring consist of 5 questions: 1-2+ pre-frail; 3+ frail Baseline, Mid (~5 weeks), End (~3 months) and 6 months
Secondary Anxiety PROMIS Anxiety short forms will assess anxiety symptoms. scale range 1-5: 1 (never) to 5 (always) Baseline, Mid (~5 weeks), End (~3 months) and 6 months
Secondary Therapeutic Alliance therapeutic alliance assessed using the Working Alliance Inventory Short-Form Mid (~5 weeks), End (~3 months)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A